Search
Zidovudine
go.drugbank.com/drugs/DB00495ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. … The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription.
Nefopam
go.drugbank.com/drugs/DB12293ApprovedInvestigationalWithdrawnNefopam has been investigated for the prevention of Kidney Transplantation.
Ziftomenib
go.drugbank.com/drugs/DB17171ApprovedInvestigational[A274738] This drug was approved by the FDA on November 13th, 2025, for the treatment of relapsed or refractory acute myeloid leukemia (AML) in adults with a susceptible NPM1 mutation who have no satisfactory
Palifosfamide
go.drugbank.com/drugs/DB05668InvestigationalIfosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Rebamipide
go.drugbank.com/drugs/DB11656ApprovedInvestigationalRebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.
Biopterin
go.drugbank.com/drugs/DB03886ExperimentalA natural product that has been considered as a growth factor for some insects. [PubChem]
Methapyrilene
go.drugbank.com/drugs/DB04819ApprovedWithdrawnMethapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Meticillin
go.drugbank.com/drugs/DB01603ApprovedInvestigationalOne of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.